Featured Trial:
Melanoma Prevention Study

Featured Trial:
Breast Cancer Recurrence

Featured Trial:
Bladder Cancer Treatment

Featured Trial:
Pancreas Cancer Treatment

Featured Trial:
Stomach Cancer Treatment

Featured Trial:
Young Adult Cancer
Survivors

Featured Trial:
Pancreatic Cyst Monitoring

Featured Trial:
Myeloma Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

March 4, 2026

Categories

Press Releases

Press Release: ECOG-ACRIN Cancer Research Group announces the retirement of Robert Gray after 25 years as group statistician

March 2, 2026

Categories

Announcements

Announcement: Group Statistician, Therapeutics, Leadership Transition

February 27, 2026

Categories

The February 2026 News from ECOG-ACRIN blog is now available

February 13, 2026

Categories

The Winter 2026 advocacy blog Considering Clinical Trials is now available

February 9, 2026

Categories

News Stories

Natasha Edwin, MD, community co-chair of the ECOG-ACRIN Myeloma Committee, highlights why patients in rural areas need access to quality clinical trials

Posts

ECOG-ACRIN Cancer Research Group Follow 8,912 6,498

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

13 Mar 2032471884801986872

#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: https://bit.ly/mm1oa-ea02-study

Reply on Twitter 2032471884801986872 Retweet on Twitter 2032471884801986872 0 Like on Twitter 2032471884801986872 1 Twitter 2032471884801986872

ECOG-ACRIN Cancer Research Group @eaonc ·

13 Mar 2032456785940918575

Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial

Reply on Twitter 2032456785940918575 Retweet on Twitter 2032456785940918575 0 Like on Twitter 2032456785940918575 0 Twitter 2032456785940918575

ECOG-ACRIN Cancer Research Group @eaonc ·

13 Mar 2032441978328060073

#FindingsFriday: Checkpoint blockade continues to reshape #HodgkinLymphoma treatment. E4412, recently published in @BloodPortfolio, shows that adding ipilimumab to BV + nivolumab did not significantly improve CR rates; safety profiles were similar. More:

A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with...

Key Points. BV/Ipi/Nivo did not improve CR rates over BV/Nivo; higher grade rash with the triplet was the only d...

bit.ly

Reply on Twitter 2032441978328060073 Retweet on Twitter 2032441978328060073 0 Like on Twitter 2032441978328060073 1 Twitter 2032441978328060073

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).